GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Capex-to-Revenue

Accelerated Pharma (Accelerated Pharma) Capex-to-Revenue : 0.00 (As of Mar. 2017)


View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Accelerated Pharma's Capital Expenditure for the three months ended in Mar. 2017 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2017 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Accelerated Pharma Capex-to-Revenue Historical Data

The historical data trend for Accelerated Pharma's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Capex-to-Revenue Chart

Accelerated Pharma Annual Data
Trend Dec14 Dec15 Dec16
Capex-to-Revenue
- - -

Accelerated Pharma Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Capex-to-Revenue Get a 7-Day Free Trial - - - - -

Competitive Comparison of Accelerated Pharma's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accelerated Pharma's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's Capex-to-Revenue falls into.



Accelerated Pharma Capex-to-Revenue Calculation

Accelerated Pharma's Capex-to-Revenue for the fiscal year that ended in Dec. 2016 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.002) / 0
=N/A

Accelerated Pharma's Capex-to-Revenue for the quarter that ended in Mar. 2017 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accelerated Pharma  (NAS:ACCP) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Accelerated Pharma Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Accelerated Pharma (Accelerated Pharma) Business Description

Traded in Other Exchanges
N/A
Address
Website
Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines